Minerva Surgical (NASDAQ:UTRS – Get Rating) and Sintx Technologies (NASDAQ:SINT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Institutional & Insider Ownership
42.4% of Minerva Surgical shares are held by institutional investors. Comparatively, 7.2% of Sintx Technologies shares are held by institutional investors. 0.8% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Minerva Surgical and Sintx Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Minerva Surgical currently has a consensus target price of $13.25, indicating a potential upside of 358.48%. Sintx Technologies has a consensus target price of $2.75, indicating a potential upside of 470.54%. Given Sintx Technologies’ higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Minerva Surgical.
This table compares Minerva Surgical and Sintx Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Minerva Surgical and Sintx Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Minerva Surgical||$52.10 million||1.60||-$21.46 million||N/A||N/A|
|Sintx Technologies||$610,000.00||19.53||-$8.77 million||N/A||N/A|
Sintx Technologies has lower revenue, but higher earnings than Minerva Surgical.
Minerva Surgical beats Sintx Technologies on 6 of the 10 factors compared between the two stocks.
Minerva Surgical Company Profile (Get Rating)
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Sintx Technologies Company Profile (Get Rating)
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.